NantKwest and ImmunityBio to Present at the Jefferies Virtual Healthcare Conference
26 5월 2020 - 10:30PM
Business Wire
NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today
announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both
companies, will present at the Jefferies Virtual Healthcare
Conference on June 3, 2020 at 4:30 pm ET.
The presentation will be webcast live and can be accessed
through the NantKwest and ImmunityBio websites, NantKwest.com and
ImmunityBio.com. An archived replay will be available on the
websites for approximately 30 days.
About NantKwest
NantKwest (NASDAQ: NK) is an innovative, clinical-stage
immunotherapy company focused on harnessing the power of the innate
immune system to treat cancer and virally-induced infectious
diseases. NantKwest is the leading producer of clinical dose forms
of off-the-shelf natural killer (NK) cell therapies. The activated
NK cell platform is designed to destroy cancer and virally-infected
cells. The safety of these optimized activated NK cells—as well as
their activity against a broad range of cancers—has been tested in
Phase I clinical trials in Canada and Europe, as well as in
multiple Phase I and II clinical trials in the United States. By
leveraging an integrated and extensive genomics and transcriptomics
discovery and development engine, together with a pipeline of
multiple, clinical-stage, immuno-oncology programs, NantKwest’s
goal is to transform medicine by delivering off-the-shelf living
drugs-in-a-bag and bringing novel NK cell-based therapies to
routine clinical care. NantKwest is a member of the NantWorks
ecosystem of companies. For more information, please visit
www.nantkwest.com.
haNK is a registered trademark of NantKwest, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include statements concerning or
implying that NantKwest will be successful in improving the
treatment of cancer and/or Covid-19. Risks and uncertainties
related to this endeavor include, but are not limited to, obtaining
FDA approval of NantKwest’s NK cells, as well as other
therapeutics, as part of the NANT Cancer Vaccine platform as a
cancer treatment and/or Covid-19 treatment.
Forward-looking statements are based on management’s current
expectations and are subject to various risks and uncertainties
that could cause actual results to differ materially and adversely
from those expressed or implied by such forward-looking statements.
Accordingly, these forward-looking statements do not constitute
guarantees of future performance, and you are cautioned not to
place undue reliance on these forward-looking statements.
These and other risks regarding NantKwest’s business are
described in detail in its Securities and Exchange Commission
filings, including in NantKwest’s Quarterly Report on Form 10-Q for
the Quarter ended March 31, 2020. These forward-looking statements
speak only as of the date hereof, and we disclaim any obligation to
update these statements except as may be required by law.
About ImmunityBio
ImmunityBio, Inc. is a privately held immunotherapy company with
a broad portfolio of biological molecules at clinical stages of
development. The Company’s goals are to employ this portfolio to
activate endogenous Natural Killer (NK) and CD8+ T cells in the
fields of cancer and infectious disease. Specifically, in regards
to cancer, ImmunityBio’s goal is to develop a memory T-cell cancer
vaccine to combat multiple tumor types—without the use of high-dose
chemotherapy. Regarding infectious disease, the Company is
addressing HIV, influenza, and the coronavirus SARS-CoV-2.
The Company’s first-in-human platform of technologies has
enabled it to achieve one of the most comprehensive, late-stage
clinical pipelines, activating both the innate (natural killer
cell) and the adaptive immune systems. The product pipeline
includes an albumin-linked chemotherapeutic (Aldoxorubicin), a
novel IL-15 cytokine superagonist (N-803), checkpoint inhibitors,
macrophage polarizing peptides, bi-specific fusion proteins
targeting TGFb and IL-12, adenovirus, and yeast vaccine therapies
targeting tumor-associated antigens and neoepitopes.
In December 2019, the U.S. Food and Drug Administration (FDA)
granted Breakthrough Therapy Designation to N-803 for
BCG-unresponsive CIS non-muscle invasive bladder cancer (NMIBC).
Other indications currently at registration-stage trials include
BCG-unresponsive papillary bladder cancer, first- and second-line
lung cancer, and metastatic pancreatic cancer.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include statements concerning or
implying that ImmunityBio will be successful in improving the
treatment of cancer, the novel coronavirus, and other diseases.
Risks and uncertainties related to this endeavor include, but are
not limited to, the company’s beliefs regarding the success, cost,
and timing of its development activities, clinical trials and
obtaining regulatory approval.
Forward-looking statements are based on management’s current
expectations and are subject to various risks and uncertainties
that could cause actual results to differ materially and adversely
from those expressed or implied by such forward-looking statements.
Accordingly, these forward-looking statements do not constitute
guarantees of future performance, and you are cautioned not to
place undue reliance on these forward-looking statements. These
forward-looking statements speak only as of the date hereof, and we
disclaim any obligation to update these statements except as may be
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200526005121/en/
Media Contact: Jen Hodson Jen@nant.com 562-397-3639
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024